Evamore

Evamore is a pre-clinical stage biotechnology company based in the United Kingdom that specializes in the discovery and development of precision medicines for cancer. The company utilizes a proprietary platform to identify and target cancer-specific protein isoforms that result from alternative splicing or genetic mutations unique to malignant cells. By focusing on these tumor-specific targets, Evamore aims to develop small molecule therapeutics with enhanced efficacy and significantly reduced systemic toxicity compared to traditional therapies. The company was founded by leading scientists from the University of Cambridge and is backed by prominent venture investors. Its current research efforts are focused on high-value targets across various solid tumor indications.